Oxford - OMass Therapeutics ('OMass'), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high definition, announces the publication of a novel, highly enabling native mass spectrometry approach that marks a significant technical advance in the field.
In this study OMass scientists, in collaboration with researchers from
Joint OMass Founders, Dr
'This study not only highlights the exciting potential of novel native MS technologies but also demonstrates our continued commitment to technology development and pushing the boundaries of what is possible with our platform,' said
'Nature Methods selects publications based on their ability to demonstrate novel approaches to challenging and high-interest problems in basic biology research, enabling researchers to explore new corners of biology,' commented Professor
Contact:
Tel: +44 (0)7818 430877
Email: juliawilsonuk@gmail.com
About OMass Therapeutics
OMass is harnessing native mass spectrometry and other biophysical technologies to drive drug discovery in high definition. The company's suite of proprietary technologies delivers superior resolution to traditional pharmacology assays enabling a clearer, more detailed picture of how a putative ligand engages a protein target assessing binding and function in parallel. The additional information obtained in the OMass assays can reveal new biology even at well-studied receptors and the cell-free system is unbiased for different ligand chemistries unmasking chemical space of high therapeutic potential inaccessible to cell-based assays. The company is building a pipeline of small molecule therapeutics to bring life-changing benefits to patients suffering from immunology and genetic disorders. OMass is backed by
(C) 2020 Electronic News Publishing, source